Introduction "New" proteins will continue to be discovered, and suitable names for them should be sought. In many instances preliminary symbols are introduced which serve a practical purpose until the proteins have been characterised and appropriate descriptive names can be chosen.
Using modem molecular biological methods, the existence of a protein may be suspected before it has ever been seen on an analytical gel. By cloning and gene manipulaton it may also be possible to produce proteins that may never appear in the human body. This raises a fundamental question: when should the specific protein be regarded as such and be given a proper name? When the DNA sequence is determined? When the specific mRNA is formed? When single polypeptides emerge from ribosomes? When glycosylated or otherwise modified polypeptides are detected within the cell? When complexes of more than one polypeptide chain are formed? Or when the functionally active substance is released?
The very fact that such questions have not yet been discussed in depth in the scientific literature, let alone been covered by international conventions, suggests that the problems involved are difficult to address.
In a time when biological sciences are becoming increasingly dominated by patents and their use for commercial purposes, it is not surprising that different scientific groups may be reluctant to agree that they are, in fact, working with the same protein: it might spoil the chance of obtaining a separate patent. In the case of calprotectin, which will be used as an example below, scientists have been unwilling to exchange reagents or use proper analytical methods to clarify whether various groups were working with the same protein.
There is a good tradition and sound basis for giving descriptive names for well characterised, functional proteins. Their genes should also be named accordingly. As characterisation and delineation of biological activities may take considerable time, the use of preliminary symbols or short notations for proteins will still be necessary.
Polypeptides can be subdivided into: oligopeptides (five amino acids); polypeptides (six to 40 amino acids); and proteins (>40 amino acids, corresponding to a molecular mass of about 5 kDa). Some proteins are more complex and may have carbohydrate side chains or consist of complexes of two or more polypeptide chains (oligomeric proteins). The term quaternary structure has been introduced for specific, complex oligomeric proteins. Individual polypeptide chains are called protomers, monomers or subunits, which combine to form homo-(one chain type only) and hetero-oligomers (different chain types encoded by different genes)-for example, heterodimers.
Oligomeric protein subunits are mainly joined by non-covalent bonds, although covalent, disulphide bonds occur between cysteine residues and may confer additional stability on the quaternary structure of the protein.
MATERIALS AND METHODS FOR STUDYING PROTEIN STRUCTURE
Degradation during purification of protein, for instance by lysosomal enzymes or enzymes involved in specific activation or inactivation, must be avoided.
Conventional sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (SDS-PAGE) and two dimensional electrophoresis using isoelectric focusing in the first dimension and SDS electrophoresis in the second, are standard procedures for determining the molecular mass and composition of oligomeric proteins. Isolation and purification of calprotectin Neutrophil granulocytes were isolated from standard units of citrated (CPD) blood from the blood bank as described previously,' except that EDTA-K, was added to a final concentration of 2-5 mM within one hour of venepuncture. The cells were resuspended in four volumes of 20 mM sodium barbital, 0-75 mM EDTA-K2, 10 mM diisopropylfluorophosphate (DFP) (pH 7 5). The cytosol fraction was isolated as described by Dale et al. 2 Calprotectin was purified by anion exchange chromatography on a 2-5 x 10 cm column packed with DEAE-Sepharose FastFlow (Pharmacia, Uppsala, Sweden), equilibrated with 20 mM sodium barbital and 0 75 mM EDTA-K2 (pH 7 5) . After washing out non-bound proteins, calprotectin was eluted with 20 mM sodium barbital and 10 mM calcium chloride (pH 7 5) . The eluate was concentrated by ultrafiltration using an immersible-CX filter (Millipore, Bedford, MA, USA). The concentrate was run on a 2-5 x 30 cm Sephadex G-25 column (Pharmacia) equilibrated with 50 mM ammonium bicarbonate, and then lyophilised. The dry protein dissolves rapidly in water or buffer. Enzymatic degradation of calprotectin was then carried out by granulocyte derived lysosmal proteins. The granulocytes were isolated as described earlier, except that DFP was omitted.
The cells were disrupted2 and centrifuged at 100 000 x g for 60 minutes. The lysosome rich sediment was harvested and resuspended in four volumes of 0 34 M sucrose, 20 mM imidazole, 2 mM ATP, 5 mM EGTA, 5 mM DTT, and 0-1% Triton X-100. The suspension was frozen and thawed three times, centrifuged at 100 000 x g for 60 minutes and the supemratant fluid harvested and used as the enzyme solution (E*). Mixtures each of the chains.'4 No reactivity was found in the fractions corresponding to a molecular mass below 36 kDa. The same was found when crude granulocyte extracts or purified calprotectin was tested. When the gel filtration buffer contains EDTA, about 85% of the calprotectin in plasma elutes at a molecular mass of about 36 kDa, and the rest between 100 and 300 kDa. If the buffer contains calcium, the major calprotectin peak occurs at 70 kDa, suggesting that the protein has dimerised (Fagerhol, unpublished data) .
Calprotectin is also excreted in stools. ' The letters A and B in addition to calgranulin are less informative than the alternatives light and heavy chains or numerals 8 and 14, which reflect the molecular masses of the subunits.
Conclusions and suggestions
Nomenclature of proteins has often caused controversy for several obvious reasons. It would be very useful if the World Health Organisation or another international body could take the responsibility for working out consensus rules for protein nomenclature including that of complex oligomeric proteins like calprotectin and the rapidly growing number of cytokines.
In naming proteins, scientists should carefully consider data collected by different analytical methods, recognising their limitations, before suggesting names for putative new proteins. Preferably, names should be descriptive and relate to the proteins as they are found in what may be regarded as the native, biologically active form in cells, tissues or biological fluids.
In early stages when data are lacking, preliminary and brief symbols are useful, and should preferably reflect the origin and one or more properties of the polypeptide/protein. An example might be MRP-8, short for a myelomonocyte related protein with a molecular mass of 8 kDa. As several proteins may have similar masses, p8 alone may be ambiguous.
When further analyses have revealed that the protein is a subunit of the functional protein, the latter should be given a proper name. Using calprotectin as an example, it might be referred to as a hetero-oligomer consisting of the calprotectin p8 and p14 subunits.
